MAP2K7 and non-small cell lung carcinoma: A study found that MEK inhibitor in combination with CDK4/6 inhibitor has significant anti-KRAS-mutant NSCLC (Non-Small Cell Lung Cancer) activity and radiosensitizing effect in preclinical models26.